Company / Shareholders' Equity
Ernexa Therapeutics Inc. Shareholders' Equity History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$1.7M
FY2025
5-year range
$1.7M / $12.1M
FY2021-FY2025
Trend
-23.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 10 years, ranging from $2M in FY2025 to $12M in FY2023.
Based on SEC 10-K filings.
$2M in FY2025 with a 10-year CAGR of -17.0%.
Declined from $12M to $2M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -19.7%
- 10-Year CAGR
- -17.0%
Key checks
Key Insights
- 5-year CAGR of -19.7%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 23.8% year-over-year.
- Peak shareholders' equity was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.7M | -23.8% |
| FY2024 | $2.2M | -81.6% |
| FY2023 | $12.1M | +137.8% |
| FY2020 | $5.1M | -26.4% |
| FY2019 | $6.9M | +24.9% |
| FY2018 | $5.5M | +36.1% |
| FY2017 | $4.1M | +5.7% |
| FY2016 | $3.8M | -64.8% |
| FY2015 | $10.9M | +18.7% |
| FY2014 | $9.2M | +16.6% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026